PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35218354-11	2022	Ruxolitinib blocks chemotaxis through inhibition of SG-MSC production of CXCL9, CXCL10, and CXCL11.	ruxolitinib	0-11	C-X-C motif chemokine ligand 10	Homo sapiens	80-86	
34422627-7	2021	Recombinant human CXCL10 induced JAK-STAT and PD-L1, while the CXCL10-CXCR3 and JAK-STAT inhibitors AMG487 or ruxolitinib reduced the expression of PD-L1 in HFF-1 cells.	ruxolitinib	110-121	C-X-C motif chemokine ligand 10	Homo sapiens	63-69	
32562787-11	2020	In this model, we showed that ruxolitinib significantly prevented the upregulation of pro-inflammatory M1 markers (TNFalpha, CXCL10, NOS2) and pro-fibrotic M2 markers (Arg1 and Chi3L3).	ruxolitinib	30-41	C-X-C motif chemokine ligand 10	Homo sapiens	125-131	
27892610-3	2017	Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.	ruxolitinib	29-40	C-X-C motif chemokine ligand 10	Homo sapiens	106-112